New shot may beat standard pill for chemo nausea

NCT ID NCT02106494

Completed Symptom relief Sponsor: Heron Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 3 trial tested whether a new drug called APF530, given as a shot under the skin, works better than the standard drug ondansetron for preventing nausea and vomiting after strong chemotherapy. About 942 cancer patients took part. The study compared both drugs when combined with two other anti-nausea medicines. The main goal was to see if more people had no vomiting and didn't need extra rescue medication in the 24 to 120 hours after chemo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: APF530 (a long-acting anti-nausea drug given as an injection under the skin)
What this could lead to: If it works, this could offer a more convenient, longer-lasting option to prevent nausea and vomiting after chemotherapy, reducing the need for rescue medications.
What could go wrong: This is a completed phase 3 trial, but results may not show a clear advantage over the standard treatment. Also, APF530 is a new formulation, so long-term safety data are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer chemotherapy-induced toxicity Vomiting

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

Contacts and locations

Show contact details

Locations

Arizona Oncology Associates, PC-HAL

Phoenix, Arizona, 85016, United States
Compassionate Cancer Medical Center

Riverside, California, 92501, United States
Gabrail Cancer Center Research

Canton, Ohio, 44718, United States
North Shore Oncology

East Setauket, New York, 11733, United States
Northern Indiana Research

Mishawaka, Indiana, 46545, United States
Northern Indiana Research

South Bend, Indiana, 46804, United States
The Oncology Institute of Hope and Innovation

Downey, California, 90241, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.